Genital Warts caused by HPV – treatment, recurrence, research 2018

What should you know about genital warts caused by HPV?

Anogenital warts typically develop approximately 2–3 months after HPV infection (almost all caused by types 6 or 11); however, not all persons infected with HPV types 6 and 11 develop genital warts. Anogenital warts should be assessed by a clinician and can be treated, although many warts (20–30%) regress spontaneously. Recurrence of anogenital warts within 3 months is common (approximately 30%), whether clearance occurs spontaneously or following treatment.

Read the whole manual about HPV and genital warts:

https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html

What is the most effective treatment against genital warts?

The most effective treatment (with the lowest recurrences) is called Photodynamic Therapy. Unfortunately this treatment is not available in the Western world. I mean: it is possible to get Photodynamic Therapy against i.e. ACNE on face, but it’s not possible to get it against genital warts. Why? I have no idea. Maybe it is a some kind of conspiracy? Anyway the fact is one: HPV virus hides in the skin, and it is possible to eradicate it during a few ALA-PDT treatments.

There were many clinical trials about Photodynamic therapy, but usually in China. You can check this PDF file:

https://www.cdc.gov/std/tg2015/evidence-tables/hpvtableevidence-genitalwarts-2015.pdf

What is the biggest problem with genital warts?

The biggest problem with genital warts is that they can come back, especially in the first months after their show up. All available methods (Cryotherapy, Podophyllotoxin, Aldara, Veregen…) have high recurrence rates.

What can you do to lower genital warts recurrence rate?

You can take medicinal mushrooms to boost your immune system (for example:  Coriolus versicolor and Reishi had 88% clearance rate after 2 months, during one clinical trial).

You can try food supplements like Ellagic Acid and Annona Muricata extract.  In one clinical trial EA+AM gave 74% HPV clearance rate after 6 months.

You can try use Panavir gel topically. Panavir is an antiviral medicine created in Russia. It works antiviral and immunostimulating. There are many russian clinical trials about its effectiveness.

http://poi555.com/2018/01/panavir-from-russia-alternative-treatment-for-hpv-and-genital-warts/

You can try hypethermia (44-45 celsius degree) on your genitals, but it might be hard to get this treatment in any clinic.

You can combine removing warts with taking Inosine Pranobex (3g daily for 4 weeks).

If you have strong recurrences – you should check your glucose level in blood. If you have diabetes, then you should know that there is correlation between the strength of HPV/number of recurrences and diabetes.

So what can you do?

Option A:

You can go to China and try to get Photodynamic Therapy (ALA-PDT) against genital warts. That’s the most expensive option.

Option B:

You can try Cryotherapy or Podophyllotoxin, and be mentally prepared for recurrences.

Option C:

You can try Cryotherapy or Podophyllotoxin, and 1 immune-booster (i.e. medicinal mushrooms, Ellagic acid + Annona Muricata extract)

Option D:

You can try Cryotherapy or Podophyllotoxin, 1 immune-booster and – topically – Panavir gel. Panavir gel should be applied 2 times daily (5 days before the treatment, 10 days after the treatment).

YOU CAN BUY PANAVIR AT OTC ONLINE STORE

Option E:

Combine Cryotherapy or Podophyllotoxin with Inosine Pranobex: 3g daily (1g in the morning/afternoon/evening) for 4 weeks. If you do this, then the chances for recurences are as low as 6-7%.

What about ALDARA?

If you are a man, then it’s a total waste of time.
If you are a woman, then you can try it (it has 60% effectiveness in females).

What about ACV, Thuja, homeopathic medicines?

Forget about it. It’s your health. Don’t waste your time on methods without any clinical trials. You can check Google Scholar and search for clinical trials.

Panavir from Russia – alternative treatment for HPV and genital warts

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Biologically active substance of Panavir is ”GG17” – plant polysaccharide from Solanum tuberosum. GG17 is a high-molecular hexose glycoside with complex structure: Glucose (38,5%), Galactose (14,5%), Rhamnose (9%), Mannose (2,5%), Xylose (1,5%), Uronic acid (3,5%).

Preparation was developed by the company National Research Company jointly with Research Institute of Physicochemical Medicine, Ministry of Health and Social Development of the Russian Federation, under the direction of the academician of RAMS Sergienko V.I.

CLINICAL STUDY 1

This research is devoted to determination of the clinical efficacy of Panavir in the combined therapy of the uterine cervix diseases associated with human papillomavirus (HPV). The article presents data of the complex examination of 59 patients. Patients with diagnosed 16th, 18th, 31st, 33rd types of HPV underwent destructive methods of treatment of the cervix followed by Panavir. The efficacy of Panavir was estimated by PCR in 3, 6 and 12 months from the beginning of treatment and it was 84,7%. Antiviral therapy permits to prevent recurrence of papillomavirus infection of the cervix uteri.

http://journals.rudn.ru/medicine/article/view/3463

CLINICAL STUDY 2

All the patients were given Panavir rectal suppositories in a daily dose of 200 mg for 10 days. Radio waves were used to destroy anogenital warts in Group 1 patients. The patients were examined using laboratory monitoring immediately and 30, 60, and 90 days after therapy. Results. Following 3 months of Panavir therapy in combination with radio wave mass destruction, human papillomavirus DNA was not detected in 80% of the patients; remission was recorded in 90%. After 3 months of Panavir use, 85% of the patients with latent infection were found to cease human papillomavirus DNA excretion. Conclusion. The high clinical efficacy of Panavir suppositories permits one to recommend the agent in this formulation for wide practical application.

EBSCO

CLINICAL STUDY 3

The article presents the results of treatment of 51 men with recurrent genital HPV infection in the form of genital warts. Patients were divided into two groups depending on the treatment. Group 1 of patients has received the combination treatment–electrocoagulation + pharmacotherapy (panavir intravenously and topically in the form of a gel), Group 2 of patients–only electrocoagulation. According to the results of follow-up within 6 months, disease recurrence rate was significantly higher in Group 2–39.5% versus 9.6% in the Group 1. Postoperative complications were also more frequently recorded in the Group 2. These findings suggest that the combined treatment of reccurent forms of genital warts is preferred than just using destructive methods of treatment.

https://www.ncbi.nlm.nih.gov/pubmed/24649765

CLINICAL STUDY 4

The efficiency of combined therapy in patients with HPV-associated chronic endocervitis was investigated. The antiviral preparation modulating immune response (panavir) was used. The results showed that panavir increases the efficiency of therapy and eliminates the HPV in 96,6% of patients.

ResearchGate

CLINICAL STUDY 5

The results of combination therapy were comparatively analyzed in 60 patients with human papillomavirus (HPV)-associated cervical neoplasias. Thirty patients in the study group were given the antiviral and immunomodulatory drug – intravenous and intravaginal panavir before destructive treatment. Thirty patients in the control group had traditional destructive treatment. It has been ascertained that the use of systemic and local combination antiviral therapy before destructive treatments enhances the efficiency of the therapy performed, promotes a reduction in process relapsing, and leads to HPV elimination in 85% of cases.

https://elibrary.ru/item.asp?id=18911191

IMPORTANT:

I found informations about Panavir when I was searching for clinical trials about HPV and genital warts. I have learned that Panavir is very effective in combined therapy. It lowers recurrences of genital warts and increase the speed of HPV clearance.

I think that the best approach is combined therapy: Cryotherapy (or Podophyllotoxin) to remove genital warts, and Panavir gel to avoid recurrences.

If you want,  YOU CAN BUY PANAVIR AT OTC ONLINE STORE.

Natural HPV treatment: Ellagic acid and Annona Muricata – strong antiviral herbs

It seems that we have a new natural treatment for HPV infections.

Journal of Functional Foods published article “Antiviral activity of Ellagic acid and Annona Muricata in cervical HPV related pre-neoplastic lesions: A randomized trial” about Ellagic acid and Annona Muricata, two natural ingredients that fights with HPV virus:

Ellagic acid (EA) and Annona Muricata (AM) have antioxidant, anticarcinogenic and antiviral activity demonstrated by in vitro models. This pilot study investigated the in vivo potential anti-viral activity in women affected by Low squamous intraepithelial lesion (L-SIL) related to high risk human papilloma virus (HR-HPV), and the ability to modify the oncoproteins expression in the cervical lesion thickness. Sixty women affected by HR-HPV related L-SIL, were randomly divided into two groups: group A (n = 30) supplemented with EA (16 mg) + AM (100 mg) 2 times daily for 6 months and group B (n = 30) administered with placebo. HR-HPV clearance was obtained in 74% of cases in group A compared to 25% of cases in group B (p = 0.001) and p21 expression in LSIL thickness increased in 63.2% of cases in group A compared to 20% in group B (p = 0.03). AE/AM supplementation significantly induces HR-HPV elimination and stimulates p21 expression in LSIL thickness.

See the whole article:

http://www.sciencedirect.com/science/article/pii/S1756464617303225

So as for now we have at least 2 very effective natural treatments for HPV:
– mushroom extracts from Coriolus Versicolor + Reishi, 88% clearance after 2 months
– Ellagic acid and Annona Muricata, 74% clearance after 6 months

More informations about ellagic acid:

Ellagic acid is a Polyphenol compound found in numerous fruits and vegetables, including, raspberries; strawberries; cranberries; walnuts; pecans; pomegranates; and other plant foods. It is often regarded as an antioxidant. Ellagic Acid Clinical Tests on cultured human cells also show that Ellagic acid prevents the destruction of the p53 gene by cancer cells. Additional studies suggest that one of the mechanisms by which Ellagic acid inhibits mutagenesis and carcinogenesis is by forming adducts with DNA, thus masking binding sites to be occupied by the mutagen or carcinogen.

https://pubchem.ncbi.nlm.nih.gov/compound/ellagic_acid#section=Top

Remember to use EXTRACTS because they have high amounts of active ingredients.

The Strongest Antiviral Mushrooms: Reishi and Chaga – HPV treatment 2018

Reishi mushroom extracts contains such active ingredients as:
– polysaccharides
– triterpenes

Chaga mushroom extracts contains such active ingredients as:
– polysaccharides
– triterpenes
– betulinic acid

Remember to use ONLY WATER EXTRACTS or ALCOHOL EXTRACTS. Avoid “powdered mushrooms” – you can’t digest chitin and – even if – they have very, very little active ingredients.

Antioxidant polysaccharides

Polysaccharides from mushrooms including Pleurotus eryngii, P. ostreatus, P. nebrodensis, Lentinus edodes, Hypsizygus marmoreus, Flammulina velutipes, Ganoderma lucidum, and Hericium erinaceus were isolated by water extraction and alcohol precipitation. Our results suggest that all tested polysaccharides have the significant antioxidant capacities of scavenging free radicals (1,1-diphenyl-2-picrylhydrazyl and hydroxyl radicals). Among them, the H. erinaceus polysaccharide exhibits the highest 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activity, whereas the L. edodes polysaccharide shows the strongest scavenging ability for hydroxyl radicals. Furthermore, using the MCF-7 breast cancer cell line and HeLa cells, all 8 selected polysaccharides are able to inhibit the proliferation of tumor cells, but the strength of inhibition varied depending on the mushroom species and the concentration used. Notably, G. lucidum polysaccharide shows the highest inhibition activity on MCF-7 cells. By comparison, H. erinaceus polysaccharide has the strongest inhibitory effect on HeLa cells. Moreover, high-performance liquid chromatography with a carbohydrate analysis column showed significant differences in polysaccharide components among these mushrooms. Thus our data suggest that the different species of mushrooms have the variable functions because of their own specific polysaccharide components. The 8 mushroom polysaccharides have the potential to be used as valuable functional food additives or sources of therapeutic agents for antioxidant and cancer treatments, especially polysaccharides from H. erinaceus, L. edodes, and G. lucidum.

http://dl.begellhouse.com/journals/708ae68d64b17c52,7b35b5ed6bb0a817,0d63c11a3ff8f73e.html

Reishi  (Ganoderma lucidum) vs. HPV

This preliminary randomized study investigated the efficacy of medicinal mushrooms, Trametes versicolor (TV), Ganoderma lucidum (GL), and Laetiporus sulphureus (LS), on the clearance of oral human papillomavirus (HPV, serotypes 16 and 18). Among 472 patients who underwent oral swabs for gingivitis, 61 patients were positive for HPV16 or HPV18. Twenty patients were included in group 1 (LS) and 41 patients were included in group 2 (TV+GL) for 2 months. Polymerase chain reaction (PCR) for HPV was performed at inclusion and after 2 months. In group 1, the clearance was equal to 5% after 2 months of treatment. In group 2, the clearance was equal to 88% (P<0.001). The detection of HPV16 or HPV18 could become relevant in routine since positivity is frequent and because a harmless and costless treatment may exist. The use of TV+GL for the clearance of oral HPV deserves further investigation.

http://dl.begellhouse.com/journals/708ae68d64b17c52,266d4152107fca7a,3512deba5cc9e72b.html

Reishi vs. bacteria

This article presents a comparative gas chromatography (GC)−mass spectrometry (MS)−based metabolomic analysis of mycelia and fruiting bodies of the medicinal mushroom Ganoderma lucidum. Three aqueous extracts−mycelia, fruiting bodies, and a mixture of them−and their sequential fractions (methanolic and ethyl acetate), prepared using an accelerated solvent extractor, were characterized by GC-MS to determine volatile organic compounds and by high-performance thin-layer chromatography to quantify ascorbic acid, a potent antioxidant. In addition, these extracts and fractions were assessed against Candida albicans and C. glabrata biofilms via the XTT reduction assay, and their antioxidant potential was evaluated. Application of chemometrics (hierarchical cluster analysis and principal component analysis) to GC data revealed variability in volatile organic compound profiles among G. lucidum extracts and fractions. The mycelial aqueous extract demonstrated higher anti-Candida activity and ascorbic acid content among all the extracts and fractions. Thus, this study illustrates the preventive effect of G. lucidum against C. albicans and C. glabrata biofilms along with its nutritional value.

http://dl.begellhouse.com/journals/708ae68d64b17c52,32c8651274405055,16650dfe7395ce6b.html

Reishi vs. cancer

In this study, we investigated the effects of the aqueous extracts of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum, obtained from three localities (China; and Morelos and Michoacan, Mexico) on cervical cells transformed by human papillomavirus (HeLa and SiHa) and C-33A cancer cells. The cells were plated in DMEM medium supplemented, and were incubated in the presence of different concentrations of G. lucidum for 24 h. Cell proliferation was determined by MTT colorimetric assay and viability by trypan blue assay. Inhibitory dose was determined (IC50) of the three different extracts of G. lucidum in the culture cell lines mentioned above. The apoptosis process was confirmed by nuclear DNA fragmentation and the cell cycle was determined by flow cytometry. The results showed that aqueous extracts G. lucidum obtained from three localities produced inhibition in the proliferation of VPH transformed cells; they also induced apoptosis and cell cycle arrest in HeLa, SiHa, and C-33A cancer cells. Therefore, it was found that aqueous extracts G. lucidum obtained from three different locations produced inhibitory effect on cancer cells and may have a potential therapeutic use for the prevention and treatment of this disease.

http://dl.begellhouse.com/journals/708ae68d64b17c52,3fd456332214676c,029d31540328ce6b.html

Reishi vs. tumors

Ganoderma lucidum has been established to be an antitumor natural product. Hot-water extracts of the mycelium of G. lucidum (GLP) exhibited antitumor effect against fibrosarcoma in male and female C3H mice and inhibited the metastasis of the tumor to the lung. Moreover, we have fractionated GLP into polysaccharide fraction [GLP(AI)] and nonpolysaccharide fraction. We found that GLP(AI) is the major component to show the in vivo antitumor effect on fibrosarcoma growth in C3H mice. The effect of PS-G purified from GLP(AI) by Sephadex and ion-exchange column chromatography on the induction of differentiation in leukemic U937 cells was examined. We found that it could stimulate blood mononuclear cells to secrete cytokines, TNF-a, IFN-g, IL-1b, and IL-6, etc., which were both antiproliferative and differentiation-inductive to the leukemic U937 and HL-60 cells. TNF-a and IFN-g, especially, induced apoptosis and differentiation in the treated leukemic cells. Furthermore, antitumor activity of G. lucidum on intraperitioneally implanted Lewis lung carcinoma in syngeneic C57BL/6 mice was investigated. The results showed that GLP significantly increased the lifespan of tumor-implanted mice, when administered intraperioneally alone or in combination with cytotoxic antitumor drugs (adriamycin, fluorouracil, thioguanine, methotrexate, or cisplatin) or a synthetic immunomodulator (imexon). The GLP was not cytotoxic to cultured cells, and the antitumor activity was abolished by pretreatment of mice with cyclosporine. These observations suggest that GLP exerts its antitumor effect mainly through immunopotentiation of the tumor-bearing animals.

http://dl.begellhouse.com/journals/708ae68d64b17c52,58cadf0c6c913237,1af485045b17e424.html

Betulinic acid from Chaga mushrooms

Betulinic Acid is a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.

https://pubchem.ncbi.nlm.nih.gov/compound/betulinic_acid#section=Top

Chaga vs. cancer

The natural compound betulinic acid shows potent anticancer activity through activation of the mitochondrial pathway of apoptosis in cancer cells. Betulinic acid may also be used in combination protocols to enhance its antitumor activity, for example with chemo- or radiotherapy or with the death receptor ligand TRAIL. Because of its relative selective cytotoxicity against malignant compared to normal cells, betulinic acid is a promising new experimental anticancer agents for the treatment of human cancers.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658785/

Alternative HPV treatments / cure research / clinical trials 2018

Photodynamic Therapy

Photodynamic therapy (PDT), sometimes called photochemotherapy, is a form of phototherapy involving light and a photosensitizing chemical substance, used in conjunction with molecular oxygen to elicit cell death (phototoxicity). PDT has proven ability to kill microbial cells, including bacteria, fungi and viruses. PDT is popularly used in treating acne. It is used clinically to treat a wide range of medical conditions, including wet age-related macular degeneration, psoriasis, atherosclerosis and has shown some efficacy in anti-viral treatments, including herpes. It also treats malignant cancers including head and neck, lung, bladder and particular skin. The technology has also been tested for treatment of prostate cancer, both in a dog model and in prostate cancer patients. It is recognised as a treatment strategy that is both minimally invasive and minimally toxic. (Wikipedia)

In case of genital warts / cancer caused by HPV it is possible to use Photodynamic Therapy (PDT) with 5-aminolevulinic acid (ALA). It’s called ALA-PDT.

For more informations check this PDF file, page no. 14 and following pages:
https://www.cdc.gov/std/tg2015/evidence-tables/hpvtableevidence-genitalwarts-2015.pdf

Immunotherapy with Virus Like Particles (VLPs)

Genital warts are caused by infection with human papillomavirus type 6 (HPV6) or less commonly the closely related HPV 11.1,2 While benign, these lesions commonly persist, with less than half of immunocompetent patients resolving infection within six months.3 Despite use of destructive therapies including electrocautery, cryotherapy, or application of podophyllotoxin or trichloroacetic acid, disease recurrence is common.4 However, generation of specific immunity to papillomavirus proteins appears important for clearance, as immunosuppressed individuals with impaired cell mediated immunity clear genital warts more slowly, and more commonly have recurrence after treatment.5

The major papillomavirus protein L1 self assembles into virus like particles, which, together with alum based adjuvants, are the basis of vaccines licensed for use for prevention of HPV infection. L1 virus like particles, in animal models, can induce strong cell mediated immune responses including cytotoxic T-cell responses if delivered without adjuvant. A phase 1 open label safety trial of unadjuvanted HPV6 VLPs (VLP immunotherapy) in patients with treatment refractory genital warts had observed regression of disease that would not have been expected from previous studies of therapy in similar patients.9 Therefore a randomized placebo controlled trial was undertaken to establish whether VLP immunotherapy could reduce the recurrence of genital warts following locally destructive therapy.

Read the whole article:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495719/

Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease

A total of 23 women with HSIL were treated with Lopimune during which time no adverse reactions were reported. A maximum concentration of 10 ng/ml of lopinavir was detected in patient plasma 1 week after starting treatment. HPV was no longer detected in 12/23 (52.2%, 95%CI: 30.6–73.2%). Post-treatment cytology at 12 weeks on women with HSIL, showed 14/22 (63.6%, 95%CI: 40.6–82.8%) had no dysplasia and 4/22 (18.2%, 95%CI: 9.9–65.1%) were now low grade demonstrating a combined positive response in 81.8% of women of which 77.8% was confirmed by histology. These data are supported by colposcopic images, which show regression of cervical lesions.

Read the whole article:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147917

Panavir – antiviral medicine from Russia

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Read the whole article:
http://poi555.com/2018/01/panavir-from-russia-alternative-treatment-for-hpv-and-genital-warts/

Combined therapy: remove genital warts + use Inosine Pranobex

This study evaluates the effectiveness of immunomodulating drug isoprinosine in a comprehensive treatment of genital warts in men. Most of the patients were aged 20-30 years. The combination therapy was found to have long term effectiveness. In the group of patients undergoing only destructive methods of treatment relapse after 8 month follow-up was diagnosed in 32% and in patients of the combination therapy group (destruction plus isoprinosine) – in 7% of patients. The pharmacological action of the drug (immunostimulating, antiviral) and the effectiveness of its combination with destructive therapies justify the use of inosine pranobex (isoprinosine) both in the complex therapy of genital warts and for the prevention of the disease recurrence.

Source